Yeztugo Alternatives Compared
| Yeztugo (lenacapavir) | Apretude (cabotegravir) | Truvada (emtricitabine / tenofovir disoproxil) |
|
|---|
| Yeztugo (lenacapavir) | Apretude (cabotegravir) | Truvada (emtricitabine / tenofovir disoproxil) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Pre-Exposure Prophylaxis of HIV. Yeztugo may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Pre-Exposure Prophylaxis of HIV. Apretude may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Pre-Exposure Prophylaxis of HIV, HIV Infection, Nonoccupational Exposure, Occupational Exposure. Truvada may also be used for purposes not listed in this medication guide. |
Related suggestions Pre-Exposure Prophylaxis of HIV
|
|||||||||||||||||||||||
| More about Yeztugo (lenacapavir) | More about Apretude (cabotegravir) | More about Truvada (emtricitabine / tenofovir disoproxil) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Be the first to share your experience with this drug. |
Apretude has an average rating of 9.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Truvada has an average rating of 6.2 out of 10 from a total of 40 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 33% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Yeztugo side effects |
View all Apretude side effects |
View all Truvada side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Yeztugo prices |
View all Apretude prices |
View all Truvada prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other lenacapavir brands include: Sunlenca | Other cabotegravir brands include: Vocabria | Other emtricitabine / tenofovir disoproxil brands include: AccessPak for HIV PEP Basic | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
2016 hours |
41 hours |
25.7 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 474 drugs are known to interact with Yeztugo:
|
A total of 66 drugs are known to interact with Apretude:
|
A total of 249 drugs are known to interact with Truvada:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
June 18, 2025 |
N/A |
August 02, 2004 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.